• Je něco špatně v tomto záznamu ?

HIV resistance testing and detected drug resistance in Europe

A. Schultze, AN. Phillips, R. Paredes, M. Battegay, JK. Rockstroh, L. Machala, J. Tomazic, PM. Girard, I. Januskevica, K. Gronborg-Laut, JD. Lundgren, A. Cozzi-Lepri, . ,

. 2015 ; 29 (11) : 1379-89.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010088

OBJECTIVES: To describe regional differences and trends in resistance testing among individuals experiencing virological failure and the prevalence of detected resistance among those individuals who had a genotypic resistance test done following virological failure. DESIGN: Multinational cohort study. METHODS: Individuals in EuroSIDA with virological failure (>1 RNA measurement >500 on ART after >6 months on ART) after 1997 were included. Adjusted odds ratios (aORs) for resistance testing following virological failure and aORs for the detection of resistance among those who had a test were calculated using logistic regression with generalized estimating equations. RESULTS: Compared to 74.2% of ART-experienced individuals in 1997, only 5.1% showed evidence of virological failure in 2012. The odds of resistance testing declined after 2004 (global P < 0.001). Resistance was detected in 77.9% of the tests, NRTI resistance being most common (70.3%), followed by NNRTI (51.6%) and protease inhibitor (46.1%) resistance. The odds of detecting resistance were lower in tests done in 1997-1998, 1999-2000 and 2009-2010, compared to those carried out in 2003-2004 (global P < 0.001). Resistance testing was less common in Eastern Europe [aOR 0.72, 95% confidence interval (CI) 0.55-0.94] compared to Southern Europe, whereas the detection of resistance given that a test was done was less common in Northern (aOR 0.29, 95% CI 0.21-0.39) and Central Eastern (aOR 0.47, 95% CI 0.29-0.76) Europe, compared to Southern Europe. CONCLUSIONS: Despite a concurrent decline in virological failure and testing, drug resistance was commonly detected. This suggests a selective approach to resistance testing. The regional differences identified indicate that policy aiming to minimize the emergence of resistance is of particular relevance in some European regions, notably in the countries in Eastern Europe.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010088
003      
CZ-PrNML
005      
20160411125834.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/QAD.0000000000000708 $2 doi
024    7_
$a 10.1097/QAD.0000000000000708 $2 doi
035    __
$a (PubMed)26091300
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schultze, Anna $u aDepartment of Infection and Population Health, University College London, London, UK bFundacions irsiCaixa i Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain cDivision of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Switzerland dUniversitäts Klinik, Bonn, Germany eDepartment of Infectious Diseases, Third Faculty of Medicine, Charles University and Hospital Na Bulovce in Prague, Czech Republic fClinic for Infectious Diseases, University Medical Centre, Ljubljana, Slovenia gService des Maladies Infectieuses, APHP, Hôpital St Antoine and INSERM, UMR_S1136, Paris, France hState Agency Infectology Center of Latvia, Riga, Latvia iRigshospitalet, University of Copenhagen, CHIP at Department of Infectious Diseases, Copenhagen, Denmark.
245    10
$a HIV resistance testing and detected drug resistance in Europe / $c A. Schultze, AN. Phillips, R. Paredes, M. Battegay, JK. Rockstroh, L. Machala, J. Tomazic, PM. Girard, I. Januskevica, K. Gronborg-Laut, JD. Lundgren, A. Cozzi-Lepri, . ,
520    9_
$a OBJECTIVES: To describe regional differences and trends in resistance testing among individuals experiencing virological failure and the prevalence of detected resistance among those individuals who had a genotypic resistance test done following virological failure. DESIGN: Multinational cohort study. METHODS: Individuals in EuroSIDA with virological failure (>1 RNA measurement >500 on ART after >6 months on ART) after 1997 were included. Adjusted odds ratios (aORs) for resistance testing following virological failure and aORs for the detection of resistance among those who had a test were calculated using logistic regression with generalized estimating equations. RESULTS: Compared to 74.2% of ART-experienced individuals in 1997, only 5.1% showed evidence of virological failure in 2012. The odds of resistance testing declined after 2004 (global P < 0.001). Resistance was detected in 77.9% of the tests, NRTI resistance being most common (70.3%), followed by NNRTI (51.6%) and protease inhibitor (46.1%) resistance. The odds of detecting resistance were lower in tests done in 1997-1998, 1999-2000 and 2009-2010, compared to those carried out in 2003-2004 (global P < 0.001). Resistance testing was less common in Eastern Europe [aOR 0.72, 95% confidence interval (CI) 0.55-0.94] compared to Southern Europe, whereas the detection of resistance given that a test was done was less common in Northern (aOR 0.29, 95% CI 0.21-0.39) and Central Eastern (aOR 0.47, 95% CI 0.29-0.76) Europe, compared to Southern Europe. CONCLUSIONS: Despite a concurrent decline in virological failure and testing, drug resistance was commonly detected. This suggests a selective approach to resistance testing. The regional differences identified indicate that policy aiming to minimize the emergence of resistance is of particular relevance in some European regions, notably in the countries in Eastern Europe.
650    _2
$a dospělí $7 D000328
650    _2
$a látky proti HIV $x terapeutické užití $7 D019380
650    _2
$a počet CD4 lymfocytů $7 D018791
650    _2
$a kohortové studie $7 D015331
650    _2
$a virová léková rezistence $x genetika $7 D024882
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genotyp $7 D005838
650    _2
$a HIV infekce $x farmakoterapie $7 D015658
650    _2
$a inhibitory HIV-proteasy $x terapeutické užití $7 D017320
650    _2
$a HIV-1 $x genetika $7 D015497
650    _2
$a lidé $7 D006801
650    _2
$a logistické modely $7 D016015
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multivariační analýza $7 D015999
650    _2
$a inhibitory reverzní transkriptasy $x terapeutické užití $7 D018894
650    _2
$a neúspěšná terapie $7 D017211
650    _2
$a virová nálož $x účinky léků $7 D019562
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Phillips, Andrew N
700    1_
$a Paredes, Roger
700    1_
$a Battegay, Manuel
700    1_
$a Rockstroh, Jürgen K
700    1_
$a Machala, Ladislav
700    1_
$a Tomazic, Janez
700    1_
$a Girard, Pierre M
700    1_
$a Januskevica, Inga
700    1_
$a Gronborg-Laut, Kamilla
700    1_
$a Lundgren, Jens D
700    1_
$a Cozzi-Lepri, Alessandro
700    1_
$a ,
773    0_
$w MED00000179 $t AIDS (London, England) $x 1473-5571 $g Roč. 29, č. 11 (2015), s. 1379-89
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26091300 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160411125916 $b ABA008
999    __
$a ok $b bmc $g 1113517 $s 934456
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 29 $c 11 $d 1379-89 $i 1473-5571 $m AIDS $n AIDS $x MED00000179
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...